Appl. No. 10/649,400 Amdt. dated November 21, 2006 Amendment under 37 CFR 1.116 Expedited Procedure Examining Group 1649

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

- 1. (currently amended) A method for determining whether a subject has or is predisposed for a mental disorder diagnosing a mental disorder in a subject, wherein the mental disorder is bipolar disorder or major depressive disorder, the method comprising the steps of:
- (i) isolating a subject's brain tissue, wherein said tissue is selected from the subject's dorsal lateral prefrontal cortex;
- (ii) contacting the subject's brain tissue with a reagent that selectively associates with a messenger RNA polynucleotide encoded by a nucleic acid gene with at least 95% identity to a gene selected from the group consisting of SEQ ID NO:1 or 3 SEQ ID NO:3;
- (iii) detecting the level of reagent that selectively associates with the <u>messenger</u> RNA sample; and
- (iv) comparing the detected level of reagent with a control, whereby if the detected level is significantly greater than the control, an increased likelihood that the subject has or is predisposed for a mental disorder bipolar or major depressive disorder is determined; and whereby, if the detected level is not significantly greater than the control, an increase in said likelihood is not determined by the method.
 - 2. (Canceled)
- 3. (Original) The method of claim 1, wherein the reagent is a nucleic acid.
 - 4 50. (Canceled)

Appl. No. 10/649,400 Amdt. dated November 21, 2006 Amendment under 37 CFR 1.116 Expedited Procedure Examining Group 1649 **PATENT**

- 51. (Previously presented) The method of claim 1, wherein the subject is deceased.
- 52. (Currently amended) The method of claim [[8]] 1, wherein the [[mood]] mental disorder is bipolar disorder.
- 53. (New) The method of claim 1, wherein the mental disorder is major depressive disorder.